Sernova and Seraxis close US$11.2M financing to fund merger into BetaNova Biotherapeutics

Sernova and Seraxis closed a US$11.2 million financing to fund their merger into BetaNova Biotherapeutics and to advance their Type 1 diabetes cell therapy into a near-term Phase 1/2 clinical trial.

Detected & updated continuously · Source: Nebula